Skip to main content
Fig. 1 | BMC Endocrine Disorders

Fig. 1

From: Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

Fig. 1

Weighted hazard ratios for HbA1c, weight, and blood pressure outcomes1,2. BP: Blood pressure; BW: Body weight; CANA: Canagliflozin; DPP-4: Dipeptidyl-peptidase-4; HR: Hazard ratio. Note: * Significant at the 5% level. 1. Based on the IPTW-weighted population. 2. Estimated using a weighted Cox proportional hazards model containing a single indicator for treatment cohort. 3. Evaluated among patients with a baseline HbA1c ≥7%. 4. Evaluated among patients with a baseline HbA1c ≥8%. 5. Evaluated among patients with a baseline BW measurement. 6. Evaluated among patients with a baseline systolic BP ≥140 mmHg. 7. Evaluated among patients with a baseline diastolic BP ≥90 mmHg

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us